Shown is the association of coding variants within ELL2 with MM risk, assessed with 513 MM cases from the UK MyIX and MyXI clinical trials and 1,569 UK controls from the UK 1958 Birth Cohort (Scales et al., 2017) . Position of SNP based on NCBI build 37 of the human genome. r 2 with respect to rs11372862. REF, reference allele; ALT, alternate allele with their allele counts in case and control populations. Also shown the MAF; minor allele frequency for cases and controls. P-value derived from Fisher's exact test (two-sided) assessing the difference in allele frequency in cases and controls. NA, SNP ID not available. Asterisk (*) denotes variants with no call rate of > 0.03 across either case or control samples. Position of SNP based on NCBI build 37 of the human genome. r 2 with respect to rs11372862. Odds ratio (OR) derived relative to the risk allele with 95% confidence interval (CI) shown. Meta P-value derived from (A) metaanalysis of the UK MyIX and MyXI and German GMMG GWAS with 3,790 cases and 7,304 controls, (B) metaanalysis of HRDMM case-control analyses from the UK and German populations with 1,363 cases and 7,304 controls.
Cases
Emboldened are SNPs within interacting fragment with ELL2 promoter (chr5: 95, 260, 264, 576 ; * in Figure  2 ). P het represents Cochran's test of between-study heterogeneity P-value. I 2 denotes the proportion of the total variation due to heterogeneity, with values ≥75% considered to be characteristic of large heterogeneity. (A) Data from the UK-GWAS (1,165 cases from the UK MRC Myeloma IX trial, UK-MyIX; 877 cases from the UK MRC Myeloma XI trial, UK-MyXI) and the German-GWAS (511 cases from the GER-GMMG trial). Shown is the hazard ratio (HR) relative to the C-risk allele with associated 95% confidence intervals (CI).
(A) UK and German GWAS

Overall survival and progression-free survival analyses comparing patients with upper and lower quartile of (B) ELL2, (C) BiP, (D) ATF6 and (E) ELL1 and (F) POU2AF1 expression. Data from 259 MM individuals from the UK MRC Myeloma IX trial (UK-MyIX; GEO: GSE21349) and 246 MM individuals from the German GMMG clinical trial (GER-GMMG; EMBL-EBI: E-MTAB-372) with expression data. Shown is the hazard ratio (HR) with associated 95% confidence intervals (CI).
(A) Relationship between rs6877329 genotypes and patient survival 
Genome-wide association study data
The UK-GWAS and German-GWAS of MM have been previously reported GWAS quality control has been described previously . To recover untyped genotypes we performed imputation using IMPUTE2 v2.3 with a combined UK10K and 1000 Genomes Project (phase 1 integrated release 3, March 2012) panel for reference (1000Genomes, 2010 Huang et al., 2015) . Poorly imputed SNPs (INFO score < 0.80) were excluded. To assess sequence variation coverage by the GWAS arrays and current imputation methods we used WGS data from 640 MM patients from the CoMMpass Study (Craig et al., 2013) . Genotypes of 18,228 variants called from the WGS data within chr5:94,700,000-96,000,000 were compared with the imputation reference panels used and the imputed genotypes from UK and German GWAS datasets.
Frequentist association testing between SNP genotype and MM was performed using logistic regression under an additive genetic model in SNPTESTv2.5 (Marchini et al., 2007) . Meta-analysis was undertaken under a fixed-effects model using inverse variance weighting in META v1.7 (Marchini et al., 2007) . To look for independent effects, conditional analysis was performed with SNPTESTv2.5 with genotypes from UK and German GWAS individuals conditioning on rs11376892. Association of germline coding variants within ELL2 with MM risk was estimated using germline WES data from 513 MM patients and 1,569 controls as detailed in Scales et al., 2017. Fisher's exact test (two-sided) was used to assess the difference in allele frequency of the coding variants in cases and controls.
Subtype detection
Karotyping was used for cytogenetic studies of MM cells and standard criteria for the definition of a clone were applied. Fluorescence in situ hybridization (FISH) and ploidy classification of UK samples was conducted using the methodologies previously described (Chiecchio et al., 2006) . FISH and ploidy classification of German samples was performed as previously described (Neben et al., 2010) . Logistic regression in case-only and case-control analyses was used to assess tumor karyotype. Meta-analysis was undertaken under a fixed-effects model using inverse variance weighting in META v1.7 (Marchini et al., 2007) .
Expression quantitative trait loci analysis
eQTL analyses were performed for CD138-purified plasma cells from 183 MRC MyIX trial patients (GEO: GSE21349) and 658 Heidelberg GMMG patients (EMBL-EBI: E-MTAB-2299) using Affymetrix Human Genome U133 2.0 Plus Array (Weinhold et al., 2015) . Briefly, German and UK data were pre-processed separately, followed by analysis using a Bayesian approach to probabilistic estimation of expression residuals to infer broad variance components, accounting for hidden determinants influencing global expression. The association between genotype of SNPs and expression of genes within 500 kb either side of rs11372862 was evaluated based on the significance of linear regression coefficients. We pooled data from the two studies under a fixed-effects model. For subtype-specific eQTL, association analyses were performed between ELL2 (22936_at), BiP (3309_at), ATF6 (22926_at) and POU2AF1 (5450_at) expression and SNPs rs11372862, rs1423269 or rs6877329 for 170 MRC MyIX trial patients and 602 Heidelberg GMMG patients with karyotype and expression data.
We carried out Summary data-based Mendelian randomization (SMR) analysis using previously established methods (Zhu et al., 2016) . As previously advocated only probes with at least one eQTL P-value of < 5.0 × 10 -8
were considered for SMR analysis. We set a threshold for the SMR test of pSMR < 0.00833 corresponding to a Bonferroni correction for 6 tests (6 probesets within 1 MB of rs11372862). We generated plots of the eQTL and GWAS associations at the locus, as well as plots of GWAS and eQTL effect sizes (i.e. corresponding to input for the HEIDI heterogeneity test). HEIDI test P-values < 0.05 were taken to indicate significant heterogeneity.
Cell lines
Human MM cell line KMS11 was obtained from the American Type Culture Collection (ATCC) and grown in Advanced RPMI 1640 Medium supplemented with GlutaMAX and 10% heat-inactivated fetal bovine serum (FBS). Human PCL cell lines L363 and JJN3 were obtained from Deutsche Sammlung von Mikroorganism und Zellkulturen GmbH (DSMZ). L363 was grown in Advanced RPMI 1640 supplemented with GlutaMAX and 15% heat-inactivated FBS. JJN3 was grown in 40% Dulbecco's MEM, 40% Iscove's MDM supplemented with 20% heat-inactivated FBS. Human lymphoblastoid cell line GM11992 were obtained from Coriell Institute and grown in RPMI 1640 culture medium supplemented with 15% FBS. Cell culture media were obtained from Life Technologies (Carlsbad, CA, USA) and FBS from PAA Laboratories (Pasching, Austria). Cells were cultured at 37°C, 100% relative humidity and 5% CO 2 . Cell lines used were confirmed to be mycoplasma-free (PCR Mycoplasma Test Kit I/C, PromoCell, Heidelberg, Germany). Genotype of rs6877329 and rs3777184 in KMS11 and GM11992 was confirmed by Sanger sequencing using sequencing primers detailed below.
Sequencing primers rs3777184 F GGAGTAGGAAGGGGAGGGTA rs3777184 R ATTGGCAGTTATCCCCAAAA rs6877329 F GAGGGGTTCTTTCCTCAAAT rs6877329 R CAAACTTACTGCAAACATTTAAACA
ENCODE and chromatin state dynamics
To explore the epigenetic profile of association signals at 5q15, we used DNAseI HS, transcription factor ChIP-seq data, histone modifications (H3K4Me1, H3K4Me3 and H3K27Ac) and ChromHMM in GM12878 from the ENCODE project (ENCODE, 2012) . ChIP-seq on H3K4Me1, H3K4Me3 and H3K27Ac histone modifications were carried out in MM cell line KMS11 and PCL cell lines L363 and JJN3. Antibodies were obtained from Diagenode (Seraing, Belgium) for H3K4Me1 (C15410194), H3K4Me3 (C15410003) and H3K27Ac (C15410196) histone modifications. We used the in silico algorithms SIFT (Kumar et al., 2009 ) and PolyPhen-2 (Adzhubei et al., 2010) to predict the impact of amino acid substitutions.
Briefly, after cell lysing, sonication of nuclei was performed (BioRuptor; Diagenode, Liege, Belgium) to obtain 150-500 bp fragments. ChIP reactions were performed on a Diagenode SX-8G IP-Star Compact using Diagenode automated Ideal Kit reagents (C01010011, Diagenode). Protein A beads were incubated for 10 hours with 3-6 μg of antibody and 2-4 million of sonicated cell lysate. ChIP samples were de-crosslinked at 65°C for 4 hours and subsequently treated for 30 minutes with RNAse Cocktail and Proteinase K. DNA was then purified (MiniElute PCR purification kit, Qiagen, Hilden, Germany), followed by library preparation according to manufacture (HTP Illumina library preparation kit, KAPA biosystem; Massachusetts, USA). Fourteen cycles of PCR were performed, followed by size selection for 200-400 bp fragments and final library purification (GeneRead Size Selection kit, Qiagen). ChIP libraries were sequenced using Illumina HiSeq 2000 (Illumina) with 100 bp single-ended reads. Generated raw reads were filtered for quality (Phred33 ≥ 30) and length (n ≥ 32), and adapter sequences were removed using Trimmomatic v0.22 (Lohse et al., 2012 ). Reads passing filters were then aligned to the human reference (hg19) using BWA v0.6.1. Peak calls are obtained using MACS2 v 2.0.10.07132012 (Feng et al., 2012) .
In situ promoter capture Hi-C
In situ promoter capture Hi-C was conducted in the cell line KMS11. In situ Hi-C libraries were prepared as previously described (Rao et al., 2014) . To increase cell lysis efficiency, 3 aliquots of 8 million cells were fixed separately in 1% formaldehyde for 10 mins, each aliquot lysed in 15 mL lysis buffer and incubated on ice for 1 hour before being combined. Cross-linked DNA was digested by restriction enzyme HindIII (NEB, Ipswich, USA). Digested chromatin ends were filled and marked with biotin-14-dATP (ThermoFisher Scientific, Waltham, USA). The resulting blunt end fragments were ligated at 16 o C in the nucleus with T4 DNA ligase (NEB) to minimize random ligation. DNA purified after crosslinking was reversed by proteinase K (Ambion, ThermoFisher Scientific) treatment. DNA was sheared by sonication (Covaris, Massachusetts, USA) and approximately 200-650 bp fragments selected. Biotin tagged DNA was pulled down with streptavidin beads and ligated with Illumina paired end adapters. Six cycles of PCR were performed to amplify libraries before capture. Promoter capture was based on 32,313 biotinylated 120-mer RNA baits (Agilent, Santa Clara, USA) targeting both ends of HindIII restriction fragments that overlap Ensembl promoters of protein-coding, non-coding, antisense, snRNA, miRNA and snoRNA transcripts. After library enrichment, a post-capture PCR step was carried out using 5 amplification cycles. Hi-C and CHi-C libraries were sequenced using Illumina HiSeq 2000 technology. Reads were aligned to the GRCh37 build using bowtie2 v2.2.6 and identification of valid di-tags was performed using HICUP v0.5.9. To declare significant contacts, HiCUP output was processed using CHiCAGO v1.1.8. Data from three independent biological replicates were combined to obtain a definitive set of contacts. The interaction within ELL2 from its promoter with the highest score was plotted. Promoter capture Hi-C on GM12878 was obtained from publically available EMBL-EBI: E-MTAB-2323 (Mifsud et al., 2015) .
Plasmid construction and luciferase assays
A 1 kb regulatory region with the risk alleles of rs6877329 and rs3777184 was amplified from human genomic DNA using primers detailed below, cloned into the PCR8/GW/TOPO vector and then transferred into pGL3 luc+ SV40-promoter vector using Gateway technology (Life Technologies). The non-risk alleles of rs6877329 and rs3777184 were generated with site-directed mutagenesis using Quick Change XL (Agilent, Santa Clara, USA). Reporter constructs were introduced into KMS11 by nucleofection, using program X-01 on the Amaxa Nucleofector I (Amaxa Biosystems, Lonza, Basel, Switzerland). 5 × 10 6 cells were resuspended in 100 µl Cell Line Nucleofector Solution V and mixed with 3 μg reporter plasmid DNA and 60 ng of internal control plasmid (pRL-SV40). Transiently transfected cells were grown for 24 hours before assaying with the Dual-Luciferase Reporter Assay System (Promega, Madison, USA) and the Fluoroskan Ascent FL plate reader (ThermoFisher Scientific). Relative luciferase activity was calculated as the ratio of luminescence from the experimental reporter to the internal control plasmid (pRL-SV40). Statistical significance was calculated using the two-tailed t-test over three biological replicates. 
Plasmid construction primers
EMSA oligos
rs6877329 C F CCCTCCGGCATCCCAGGAAGCCAGTCCATCTCTTAATTTTA rs6877329 C R TAAAATTAAGAGATGGACTGGCTTCCTGGGATGCCGGAGGG rs6877329 G F CCCTCCGGCATCCCAGGAAGGCAGTCCATCTCTTAATTTTA rs6877329 G R TAAAATTAAGAGATGGACTGCCTTCCTGGGATGCCGGAGGG
Gene expression analyses
We assessed the relationship between ELL2 and BiP, ATF6, POU2AF1, ELL1 gene expression (log 2 -transformed) in two independent MM data sets GEO: GSE21349 (259 patients from the UK MRC MyIX clinical trial) and EMBL-EBI: E-MTAB-372 (246 patients from the German GMMG clinical trial) using Pearson's product-moment correlation test. Expression data generated using Affymetrix Human Genome U133 2.0 Plus Array. P-values from the two patient data sets were combined by Fisher's Method. Statistical tests were conducted using the R software version 3.1.3.
Relationship between SNP genotype and somatic copy number
To investigate whether the risk SNP rs6877329 was preferentially amplified in heterozygous individuals with trisomy of chromosome 5 we analyzed previously published WES data on 463 MyXI trial cases (Walker et al., 2015) in conjunction with WGS and WES data on 664 cases produced by the CoMMpass Study (Craig et al., 2013) . Hyperdiploid cases were identified with chromosome 5 trisomy and amplification of at least one other odd numbered chromosome.
MyXI trial data: ExomeCNV was used to define amplification (logR > 0.1) (Sathirapongsasuti et al., 2011) . Samples were identified as heterozygous for the risk SNP if heterozygous for five coding SNPs in LD with the risk variant (r 2 > 0.95) (rs17085249, rs3815768, rs3777202, rs3777203, rs3777204).
CoMMpass data: Amplification was defined using CBS (Venkatraman and Olshen, 2007) designated copy number segments called by CoMMpass (> 50% chromosome segment.mean > 0.3). WGS and WES reads were aligned to GRCh37 build using BWA software (Li et al., 2009 ) and variants called according to GATK best practices (DePristo et al., 2011) . As the whole genome sequencing data was low coverage, the germline genotype of the risk variant was determined using itself and an additional 18 SNPs in LD (r 2 > 0.99).
57 and 50 hyperdiploid samples heterozygous for the risk variant with chromosome 5 trisomy were identified in the MyXI and CoMMpass data sets respectively. Bam-readcounts (https://github.com/genome/bam-readcount/) was used to extract the counts of reads supporting the risk and non-risk variant from the WES data at 2/5 of the coding SNPs aforementioned, separated sufficiently to out rule common reads (rs3777204 and rs3815768, separated by > 1 kb). Given the counts of risk and non-risk reads sampled at these positions, each sample was assigned to its most probable state (amplification of the risk or non-risk allele) assuming a binomial distribution of counts. In germline heterozygote samples a bias towards the mapping of a reference read was observed. An adjustment to the probabilities was therefore made using the germline ratio of reference to alternate reads to estimate the mapping bias for each SNP.
Association between rs6877329 genotypes, ELL2 expression and patient outcome
To examine the relationship between ELL2, BiP, ATF6, ELL1 and POU2AF1 expression and patient outcome, we used data from two independent patient cohorts (GEO: GSE21349, 259 patients from the UK MRC MyIX clinical trial; EMBL-EBI: E-MTAB-372, 246 patients from the German GMMG clinical trial). For each data set, patients were grouped by ELL2, BiP, ATF6, ELL1 or POU2AF1 expression (upper and lower quartiles). Analysis was performed using the log-rank test to estimate expression-associated hazard ratio and 95% confidence intervals. To examine the relationship between rs6877329 genotype and patient outcome, we analyzed GWAS data on the three patient cohorts specifically (i) 1,165 cases in the UK GWAS from the UK MRC MyIX trial; (ii) 877 MM cases in the UK GWAS from the UK MRC MyXI trial; (iii) 511 of the patients in the German GWAS from the German GMMG clinical trial. Analysis end points were myeloma-specific overall survival and progression-free survival, and analysis was performed as previously described . Cox regression analysis was used to derive genotype-specific hazard ratio and associated 95% confidence intervals.
